Secondary Listings for China Stocks: Hong Kong's Waiver Policies vs US Regulatory Pressure

The calculus for Chinese companies pursuing overseas listings has fundamentally shifted since late 2024, driven by the confluence of Hong Kong’s expanded secondary listing waivers and the escalating enforcement of the US Holding Foreign Companies Accountable Act (HFCAA). As of Q1 2025, at least 18 China-domiciled companies with US-listed ADRs have filed confidential applications for secondary listings on the Hong Kong Stock Exchange (HKEX), according to exchange filings reviewed by this publication. This represents a 50% increase over the same period in 2024, a trend directly attributable to HKEX’s revised Listing Rules introduced in November 2024, which lowered the market capitalisation threshold for a “large-cap” secondary listing from HKD 10 billion to HKD 5 billion (HKEX Listing Decision LD143-2024). Simultaneously, the US Public Company Accounting Oversight Board (PCAOB) has maintained its 2024 determination that full access to China-based audit firms remains contingent on compliance with the HFCAA, a position reaffirmed in its December 2024 annual report. For CFOs and sponsors, the strategic choice is no longer binary; it is a structured timeline arbitrage between two regulatory regimes with diverging consequences for disclosure, governance, and capital access.

The Mechanics of HKEX’s Revised Waiver Regime

HKEX’s November 2024 amendments to Chapter 19C of the Main Board Listing Rules created a bifurcated pathway for secondary listings that fundamentally alters the cost-benefit analysis for China-based issuers. The core change is the introduction of a dual-track eligibility test based on market capitalisation and revenue, replacing the previous single-threshold approach that required a minimum market cap of HKD 10 billion for all secondary listing applicants.

The HKD 5 Billion Threshold and Its Implications

Under the revised Rule 19C.04, a company seeking a secondary listing on the Main Board must satisfy either of two conditions: (a) a market capitalisation of at least HKD 5 billion at the time of listing, provided it has generated revenue of at least HKD 1 billion in the most recent financial year; or (b) a market capitalisation of at least HKD 10 billion with no revenue floor. This change is material for mid-cap China ADRs. As of 31 March 2025, of the 68 China-domiciled companies listed on the NYSE and Nasdaq with market caps between HKD 5 billion and HKD 10 billion, 23 (or 33.8%) now qualify for secondary listing under the new revenue-linked test, according to Bloomberg data. Previously, only 12 of those 68 met the HKD 10 billion threshold without a revenue requirement. The practical effect is a 91.7% expansion in the pool of eligible issuers.

Waiver of Dual-Class Share Structure Restrictions

A second critical waiver concerns the treatment of weighted voting rights (WVR) structures. HKEX’s Chapter 8A generally restricts WVR structures to “innovative companies” with a minimum market cap of HKD 40 billion. However, the November 2024 amendments to Rule 19C.09A grant an automatic waiver for secondary listings, allowing any company with a WVR structure that was compliant with its primary exchange’s rules at the time of its initial public offering to retain those rights upon listing in Hong Kong. This directly benefits the 14 China ADRs with dual-class share structures currently trading on US exchanges, including companies in the consumer internet and electric vehicle sectors. The waiver eliminates the need for these issuers to restructure their share capital, a process that typically costs between USD 1.5 million and USD 3 million in legal and advisory fees, based on fee schedules from three Hong Kong law firms reviewed for this article.

The 12-Month “Grandfathering” Window for Simplified Reporting

HKEX also introduced a transitional reporting concession under Practice Note 22. For the first 12 months following a secondary listing, the issuer is exempt from preparing its financial statements in accordance with Hong Kong Financial Reporting Standards (HKFRS) or International Financial Reporting Standards (IFRS), provided it continues to file its US GAAP accounts with the SEC. This reduces the incremental compliance burden for issuers that have historically maintained dual reporting. The SFC’s Code of Conduct for Corporate Finance Advisors (paragraph 17.6) requires the sponsor to confirm in the listing application that the issuer’s internal controls are adequate to support this transition period, but does not mandate a full IFRS conversion audit until the first full financial year after the 12-month window expires.

The US Regulatory Counterpressure: HFCAA Enforcement and PCAOB Scrutiny

The US regulatory environment for China-based issuers has not softened, despite the PCAOB’s December 2022 announcement that it had gained “full access” to inspect and investigate audit firms in mainland China and Hong Kong. The 2024 PCAOB annual report, published on 19 December 2024, explicitly states that “the Board’s ability to maintain this access is contingent on the continued cooperation of the China Securities Regulatory Commission (CSRC) and the Ministry of Finance.” This conditional language has been interpreted by US securities counsel as a signal that the PCAOB could re-impose restrictions if geopolitical tensions escalate.

The HFCAA Trading Ban Trigger

Under the HFCAA, a company is subject to a trading ban on US exchanges if the PCAOB determines that it cannot inspect the company’s auditor for three consecutive years. As of 31 March 2025, 14 China ADRs have been identified by the SEC as having “non-inspection” years for FY2022, FY2023, and FY2024, placing them at imminent risk of a trading ban in 2025. The SEC’s list, updated quarterly, includes companies with a combined market capitalisation of approximately USD 47.8 billion. The ban would prohibit these companies from trading on US national exchanges, effectively forcing a delisting unless they transfer their primary listing to Hong Kong or another jurisdiction.

The CSRC Filing Requirement as a Dual Constraint

The CSRC’s December 2023 Trial Administrative Measures of Overseas Securities Offerings and Listings impose a mandatory filing requirement for all Chinese companies seeking overseas listings, including secondary listings in Hong Kong. The filing must include a legal opinion on the issuer’s compliance with PRC data security and antitrust laws. For companies with a VIE structure—which the CSRC has acknowledged as a permissible but regulated arrangement—the filing must also include a detailed description of the VIE’s contractual control mechanism and a confirmation that the structure does not circumvent PRC foreign investment restrictions. As of Q1 2025, the CSRC has processed 37 filings for Hong Kong secondary listings, with an average review period of 72 calendar days, according to CSRC public records. This timeline must be factored into any dual-listing timetable.

Structural Arbitrage: Comparing the Two Regimes for China Issuers

For a CFO evaluating a secondary listing in Hong Kong versus a primary listing in the US, the structural differences extend beyond regulatory compliance costs to include shareholder rights, governance, and capital market access.

Shareholder Rights and Class Action Exposure

Hong Kong’s Listing Rules do not provide for a US-style securities class action mechanism. Instead, shareholders must rely on the SFC’s enforcement powers under the Securities and Futures Ordinance (Cap. 571), which allows the SFC to seek remedies for market misconduct through the Market Misconduct Tribunal. This is a fundamental difference. In the US, the Private Securities Litigation Reform Act of 1995 (PSLRA) provides a statutory framework for class actions, but the Supreme Court’s 2010 Morrison v. National Australia Bank decision limits the extraterritorial application of US securities laws to transactions on US exchanges. For a company that is dual-listed in Hong Kong and the US, shareholders who purchase shares on HKEX are generally not subject to US class action exposure for those trades. This reduces the issuer’s litigation risk profile.

The VIE Structure and the Two Regulators’ Divergent Stances

The US SEC has not issued a formal prohibition on VIE structures, but its December 2021 guidance requires all VIE-using issuers to provide clear disclosure of the structure and the associated risks. The HKEX, by contrast, has a more prescriptive approach. Under HKEX Listing Decision LD43-3, a VIE structure is only acceptable if the issuer can demonstrate that it cannot operate without the VIE due to PRC foreign ownership restrictions in its industry. The issuer must also include a VIE contractual arrangement summary in its prospectus, and the sponsor must confirm that the VIE’s variable interest entities are under the issuer’s effective control. This difference means that a company with a VIE structure that is acceptable to the SEC may not automatically qualify for a secondary listing in Hong Kong without additional restructuring.

Currency and Liquidity Considerations

Hong Kong secondary listings are typically conducted in HKD, but the HKEX introduced a dual-currency counter mechanism in June 2023 that allows issuers to trade in both HKD and RMB. For China-based issuers, the RMB counter provides a natural hedge against USD/HKD currency risk. However, liquidity in the RMB counter has been thin. As of Q1 2025, the average daily trading volume in RMB counters for secondary-listed China ADRs was HKD 1.2 million, compared to HKD 87.3 million in the HKD counter, according to HKEX data. This suggests that the HKD counter remains the primary liquidity source for institutional investors.

The 2025 Pipeline: Which Companies Are Moving and Why

The pipeline for secondary listings in 2025 is dominated by companies in three sectors: consumer internet, electric vehicles, and biotech. Each sector faces distinct regulatory pressures that accelerate the timeline.

Consumer Internet: The VIE and Data Security Overlap

For consumer internet companies with VIE structures, the primary driver is the CSRC’s data security review. Under the Measures for Data Security Management (effective 1 October 2024), any company that processes the personal information of more than one million individuals must undergo a data security assessment before listing. For a US-listed company with a VIE, the data security review must be completed before the secondary listing application is submitted to HKEX. This creates a sequential process that adds 4-6 months to the timeline. Three consumer internet companies—two in e-commerce and one in social media—have filed their data security assessments with the CSRC as of March 2025, according to CSRC filings.

Electric Vehicles: The US Tariff and IRA Exclusion

The US Inflation Reduction Act (IRA) includes provisions that exclude vehicles manufactured in China from the USD 7,500 consumer tax credit, regardless of the manufacturer’s corporate structure. For Chinese EV makers with US-listed ADRs, this has diminished the strategic value of a US listing. A secondary listing in Hong Kong provides access to Asian institutional capital and a potential listing on the Stock Connect scheme, which allows mainland Chinese investors to trade Hong Kong-listed shares. As of Q1 2025, three Chinese EV manufacturers have announced plans for secondary listings in Hong Kong, with combined fundraising targets of approximately HKD 12 billion.

Biotech: The BioSecure Act and Hong Kong Chapter 18C

The US BioSecure Act, introduced in the House of Representatives in January 2025, would prohibit US federal agencies from contracting with certain Chinese biotech companies. While the Act is not yet law, its introduction has prompted several China-based contract research organisations (CROs) and biopharma companies to explore Hong Kong listings. HKEX’s Chapter 18C, which allows pre-revenue biotech companies to list with a minimum market cap of HKD 1.5 billion, provides a viable pathway. Two biotech companies have filed for secondary listings under Chapter 18C in Q1 2025, according to HKEX listing applications.

Actionable Takeaways

1. CFOs of China ADRs with market caps between HKD 5 billion and HKD 10 billion should immediately assess eligibility under HKEX Rule 19C.04(a) and engage a sponsor to prepare a confidential filing, as the 12-month grandfathering window for simplified reporting provides a tangible cost benefit.

2. Issuers with VIE structures must complete the CSRC data security assessment before filing a secondary listing application in Hong Kong, adding a 4-6 month lead time that must be factored into any 2025-2026 timetable.

3. Companies with dual-class share structures should confirm that their WVR provisions comply with their primary exchange’s rules at the time of IPO, as HKEX’s automatic waiver under Rule 19C.09A only applies to structures that were compliant at that point.

4. The 14 China ADRs identified as having three consecutive non-inspection years under the HFCAA must assume a US trading ban is imminent in 2025 and should prioritise a Hong Kong secondary listing as a primary delisting hedge.

5. For consumer internet and EV companies, the RMB counter mechanism in Hong Kong offers a natural hedge against USD exposure, but liquidity remains concentrated in the HKD counter, so IPO pricing and placement strategies should target HKD-denominated institutional investors.